In recent years, studies have brought to light preclinical evidence of the ability of cannabinoids to reduce tumor growth in animal models, and clinical trials have been designed to study this activity in patients with glioblastoma. The data in animal models show promising results. So far it has been seen that the administration of THC is safe, and can be carried out without psychoactive effects. These molecules act through receptors coupled to the G protein, which are part of the endocannabinoid system and which have been called CB1 and CB2. THC can attenuate tumor progression in some patients, and appears to have a positive effect on survival, similar to that generated by other chemotherapeutic agents. More trials are needed to validate this antitumor action, both in combination with other therapies, and independently. At this time there is not enough scientific evidence to be able to conclusively affirm that cannabinoid treatment can contribute improve current therapies given to patients with brain tumors or other types of tumors.

In 2019, the US Center for Disease Control and Prevention provided vital statistics related to drug overdoses in the United State1. They concluded that in the USA the number of deaths at almost 72,000 was due to 66.6% of opioid overdoses. In fact, the rate is alarming and increasing yearly. To make 2021 even more scary is the daunting effect on increased drug usage due to COVID 19 as a pandemic, albeit the new vaccines. Specifically, in 2020, the death rate from opioid overdoses rose to 13% nationally and in some sates 30%. The common neuromodulating aspects of neurotransmission, and its disruption via chronic exposure of drugs and be-havioral addictions, requires further intense research focus on developing novel strategies to combat these unwanted genetic and epigenic infractions as accomplished with heroin addiction by our group.

Background:The development of individualized diagnostic profiles of children ‘at risk’ of Specific Learning Disorder (SLD) and the implementation of a well-suited to individual’s specific needs intervention program, could be of high significance for the early investigation of SLD. Materials and Methods: We assessed twenty children 5.4 to 6.0 years old aiming to the accomplishment of the following key-mile-stones: (a) implementation of an adequate cluster of diagnostic procedures, (b) formulation of individualized diagnostic profiles ‘at risk’ of SLD, and (c) implementation of intervention program, tailored to the individual’s profile. Results: According to the results, early extent of weaknesses was determined in the domains of working memory (p = .010), visuospatial abilities (p = .028), and phonological awareness (p < .001)

COVID 19 has undoubtedly been one of the biggest health challenges of present century for the whole mankind. Since almost an year whole world is desperately fighting the disease with all their available resources with limited success. Irrespective of the developmental status of a country, class or religion, whole mankind suffered huge loss in terms of human life, money, jobs and businesses and academics

Neurodevelopmental disorders are a group of complex multifactorial disorders with significant overlapping of symptoms that arise during the developmental period. This article looks into changing perspectives and evolving knowledge of these disorders as well as their future directions. These disorders can not only affect individuals but society as a whole. Accumulated knowledge of these disorders slowly began to change the perception of the disorders as well as how individuals experiencing these conditions are treated by society.

Fluid therapy (FT) was introduced during WW2. Ever since its complications have been frequently reported but notably some serious complications have been overlooked. The role of VO in inducing VOS and causing ARDS has remained unrecognized until recently, first by me and other authors are now catching up. The role of FT complications in inducing VOS and causing ARDS is hard to detect because VOS is a shock that complicates another existing shock being treated and it occurs seamlessly and unnoticed.

Background: Apathy is associated with greater caregiver burden and affects the cognitive abilities of the patient. Having a high prevalence of more than 71% in patients with dementia (PwD), it is a very common symptom in Alzheimer’s Disease (AD). In many cases it remains under-diagnosed or is misdiagnosed with depression.

It was found that the most common genotype rs2278749 ARNTL gene was homozygous C/C genotype - 74,9%. Prevalence of C/T and T/T genotype was 22.3% and 2.8%, respectively. It was revealed that persons with the genotype C/T more likely to experience serious conflicts in the family, more experienced their frustration, they often have disturbing dreams, and they wake up tired and exhausted, in addition, they often met the high level of the life of exhaustion, and they soon became frustrated. Persons with genotype T/T often took the trouble “to heart” and were more punctual. On the other hand, persons with C/C genotype were more hostile, were inclined not to trust anyone, almost “never” accept negative situations “close to the heart” and much less experienced disturbing dreams.